“After cure” is its own phase in Cushing syndrome (recovery timelines + lipid legacy)
Two Cushing-focused publications this week reinforce that endocrine “success” (biochemical control) is not the end of management—it’s the start of a monitored recovery phase. A prospective study quantified duration of adrenal insufficiency after surgical treatment of endogenous hypercortisolism and evaluated prediction using clinical severity scores—highly actionable for follow-up scheduling and patient counseling. [1]
A systematic review/meta-analysis assessed dyslipidemia patterns in Cushing syndrome and changes after treatment, reinforcing that cardiometabolic risk can persist and may not normalize uniformly across lipid fractions. [2]
Practical “tactics” to consider now:
-
Counsel on recovery timelines upfront (and document them): it reduces anxiety, supports adherence to glucocorticoid replacement, and improves sick-day preparedness.
-
Plan lipid strategy as “bridge care”: treat and reassess rather than assuming cure = lipid normalization.
-
Use severity scoring to allocate follow-up intensity (labs, taper cadence, education touchpoints).
References
-
Chacko SR, Greives J, Neves JS, et al. Duration of adrenal insufficiency after surgical treatment of endogenous hypercortisolism: a prospective study and prediction with clinical severity scores. Eur J Endocrinol. 2025;:lvaf264. https://doi.org/10.1093/ejendo/lvaf264
PubMed: https://pubmed.ncbi.nlm.nih.gov/41424030/ -
Salvio G, Sardu A, Obliquità F, et al. Dyslipidemia in Cushing syndrome and after treatment: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2025;:dgaf681. https://doi.org/10.1210/clinem/dgaf681
PubMed: https://pubmed.ncbi.nlm.nih.gov/41432529/